- Overview
- Protocols
- Specifications
- Resources
The GloResponse™ NF-?B-RE-luc2P HEK293 Cell Line is a clonal derivative of Human Embryonic Kidney 293 (HEK293) cells. These cells contain a luciferase gene (luc2P) under the control of a minimal TATA promoter with multiple Nuclear Factor-?B response elements (NF-?B-REs). NF-?B-REs are the DNA-binding sequences for the NF-?B transcription factor, which is responsible for regulating inflammation, immune response, cell growth and apoptosis. The GloResponse™ NF-?B-RE-luc2P HEK293 Cell Line is designed for rapid and convenient analysis of any cellular response that results in modulation of NF-?B activities.
The GloResponse™ Cell Lines incorporate the improvements developed for the pGL4 family of reporter vectors for enhanced performance. The destabilized luc2P luciferase reporter is used for improved responsiveness to transcriptional dynamics. The luc2P gene is codon optimized for enhanced expression in mammalian cells, and the pGL4 plasmid backbone was engineered to reduce background reporter expression. The result is a cell line with very high induction levels when the pathway of interest is activated.
GloResponse™ NF-?B-RE-luc2P HEK293 cells response to TNF-? titration. A total of 10,000 GloResponse™ NF-?B-RE-luc2P HEK293 cells per well were dispensed into each well of a 384-well plate, and twofold serial dilutions of TNF-? were added to induce reporter gene expression. After 5 hours of induction in a tissue culture incubator, luciferase activity was quantified using the ONE-Glo™ Luciferase Assay System Reagent on the Berthold® LB 96 V Luminometer. n = 8 for each data point.
-
Protocols
Complete Protocol
GloResponse™ NF-?B-RE-luc2P HEK293 Cell Line Technical Bulletin
PDF (438 KB)
-
Certificate of Analysis
Lookup Certificate of AnalysisStorage Conditions
BELOW -140C
Use Restrictions
For Research Use Only. Not for Use in Diagnostic Procedures.
-
Resources
Citations
-
Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action
--
2010 Biochem. Pharmacol.
-
Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action